CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
At the AACC show 2016
October 2016—Abingdon Health announced the CE marking and FDA registration of its immunoassay reader, the ADxLR5, as a class I medical device. The ADxLR5 lateral flow device reader is designed to offer the most up-to-date features required for rapid testing, including a touchscreen user interface, barcode sample identification, stored calibration curve processing, and Wi-Fi or wired connectivity.
The launch of the ADxLR5 will support the growth and expansion of the Abingdon Health multiple myeloma assays Seralite FLC serum and Seralite FLC urine. The ADxLR5 will be provided as an OEM reader solution for customers who wish to have a bespoke reader developed alongside the development of lateral flow assays.
Abingdon Health also announced a multiyear agreement with Sebia for distribution of its Seralite FLC Dual Kappa and Lambda serum lateral flow immunoassay. Sebia will distribute the product worldwide, except in Belgium, the Netherlands, and Luxembourg. Seralite FLC is a rapid and easy-to-operate test for the quantitative measurement of free kappa and free lambda light chains in blood. Serum free light chain (sFLC) testing is prescribed to help detect, diagnose, and monitor plasma cell disorders, such as multiple myeloma, and to monitor the effectiveness of treatments. The test is aimed at clinical laboratories with a small to medium-sized workload for sFLC test requests as well as at clinical laboratories sending requests to referral laboratories.
Abingdon Health, +44 (0) 1904 406082